Neurocrine Biosciences’ (NBIX) Buy Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Neurocrine Biosciences (NASDAQ:NBIX) in a report issued on Monday morning,Benzinga reports. They currently have a $185.00 price objective on the stock.

A number of other equities research analysts also recently weighed in on the company. Citigroup boosted their price target on Neurocrine Biosciences from $203.00 to $204.00 and gave the company a “buy” rating in a report on Thursday, February 12th. Wedbush boosted their price target on Neurocrine Biosciences from $149.00 to $151.00 and gave the company an “outperform” rating in a report on Thursday, February 12th. Mizuho boosted their price target on Neurocrine Biosciences from $146.00 to $175.00 and gave the company a “neutral” rating in a report on Friday, December 12th. Morgan Stanley reiterated an “equal weight” rating and issued a $175.00 price target (up from $173.00) on shares of Neurocrine Biosciences in a report on Thursday, January 8th. Finally, Stifel Nicolaus upped their price objective on Neurocrine Biosciences from $183.00 to $188.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $175.10.

Neurocrine Biosciences Trading Up 0.7%

Shares of NASDAQ NBIX opened at $132.48 on Monday. Neurocrine Biosciences has a twelve month low of $84.23 and a twelve month high of $160.18. The company has a market capitalization of $13.30 billion, a price-to-earnings ratio of 28.43, a price-to-earnings-growth ratio of 0.69 and a beta of 0.35. The business has a 50 day simple moving average of $131.52 and a 200-day simple moving average of $139.01.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Wednesday, February 11th. The company reported $1.88 earnings per share for the quarter, missing analysts’ consensus estimates of $2.36 by ($0.48). Neurocrine Biosciences had a net margin of 16.73% and a return on equity of 16.48%. The firm had revenue of $805.50 million during the quarter, compared to the consensus estimate of $804.21 million. During the same quarter last year, the firm posted $1.69 earnings per share. Neurocrine Biosciences’s revenue was up 28.3% compared to the same quarter last year. As a group, equities analysts predict that Neurocrine Biosciences will post 4.28 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Kyle Gano sold 36,400 shares of the company’s stock in a transaction on Friday, January 16th. The stock was sold at an average price of $132.70, for a total transaction of $4,830,280.00. Following the completion of the transaction, the chief executive officer directly owned 140,407 shares in the company, valued at $18,632,008.90. This represents a 20.59% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in NBIX. USA Financial Formulas acquired a new position in Neurocrine Biosciences during the 4th quarter worth $25,000. Geneos Wealth Management Inc. boosted its position in Neurocrine Biosciences by 143.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after acquiring an additional 135 shares during the period. Golden State Wealth Management LLC boosted its position in Neurocrine Biosciences by 120.5% during the 3rd quarter. Golden State Wealth Management LLC now owns 183 shares of the company’s stock worth $26,000 after acquiring an additional 100 shares during the period. Eastern Bank acquired a new position in Neurocrine Biosciences during the 3rd quarter worth $27,000. Finally, DJE Kapital AG acquired a new position in Neurocrine Biosciences during the 4th quarter worth $28,000. 92.59% of the stock is currently owned by institutional investors.

Trending Headlines about Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Acquisition adds a potential blockbuster and durable IP — Neurocrine agreed to buy Soleno for $53/share (~$2.9B), acquiring VYKAT XR (first FDA‑approved therapy for hyperphagia in Prader‑Willi syndrome) and intellectual property expected into the mid‑2040s, which could meaningfully broaden Neurocrine’s commercial growth runway. PR Newswire: Deal Announcement
• Positive Sentiment: Analyst support: Needham reaffirmed a Buy and set a $185 price target, signaling conviction that the deal and portfolio expansion could drive substantial upside vs. current levels. Benzinga: Needham Reaffirmation
• Neutral Sentiment: Investors can get more detail from the company’s M&A call/transcript — management hosted a call to discuss rationale and integration plans; review the transcript for specifics on financing, milestones and expected timing. Seeking Alpha: M&A Call Transcript
• Neutral Sentiment: Elevated trading activity — volume is roughly double the average, indicating active re‑rating by investors as new information (analyst notes, call details) arrives. (Background price/volume data from market feed.)
• Negative Sentiment: All‑cash $2.9B price and sizable premium raise balance‑sheet and deal‑economics concerns — Neurocrine will pay a ~34% premium to Soleno’s recent close (higher vs longer averages), which may pressure near‑term cash position and make immediate accretion less certain. Proactive Investors: Deal Terms
• Negative Sentiment: Initial investor selling and execution risks flagged by some analysts — a number of outlets reported Neurocrine stock dipped on the announcement, and BMO maintained a Hold citing longer‑term Ingrezza and orphan market execution uncertainties. These points weigh on short‑term sentiment until integration and commercial upside are clearer. TipRanks: BMO Commentary
• Negative Sentiment: Soleno’s shares surged (~30%) on the deal news — good for Soleno sellers but reflects the premium Neurocrine paid and helps explain why NBIX initially traded down on deal announcement. Economic Times: Soleno Shares Jump

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.